Abstract
The initial treatment of primary breast cancer has already been covered adequately in previous chapters. This chapter proposes to examine the possible merits associated with the use of adjuvant systemic treatment (chemotherapy or hormonal therapy) in patients whose axillary lymph nodes have proven not to contain tumor at the time of axillary dissection. Breast cancer is a common tumor and the patients with node-negative disease number about 70,000 per year in the United States.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Clinical alert from the National Cancer Institute, May 18, 1988.
Clinical alert gives breast cancer data, revises recommendations. Medical News & Perspectives. JAMA 260:153–154, 1988.
Glick JH. Meeting Highlights: Adjuvant therapy for breast cancer. Commentary. J Natl Cancer Inst 80:471–475, 1988.
Manual of Staging Cancer, 3rd ed. American Joint Committee on Cancer. J.B. Lippincott, Philadelphia, 1988
Clark GM, Dressler LG, Owens MA, Pounds George, Oldaker MT, and McGuire WL. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320:627–634, 1989.
Singh L, Wilson AJ, Baum M, Whimster WF, Birch IH, Jackson IM, Lowrye C, and Palmer MK. The relationship between histological grade, oestrogen receptor status, events and survival at 8 years in the NATO (‘Nolvadex’) trial. Br J Cancer 57:612–614, 1988.
Meyer JS and Province M. Proliferative index of breast carcinoma by thymidine labeling: Prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res Treat 12:191–204, 1988.
Kennedy BJ, Mielke PW, et al. Therapeutic castration versus prophylactic castration in breast cancer. S G and O 118:524–540, 1964.
Salmon S. Adjuvant Therapy of Cancer. Grune and Stratton, Orlando, FL, 1987.
Spratt JS and Donegan WL. Carcinoma of the breast. W.B. Saunders, Philadelphia, 1967, p. 136.
Payne W, Taylor WF, et al. Surgical treatment of breast cancer: Trends and factors affecting survival. Arch Surg 101:105, 1970.
Schatenfeld D, Nash AG, et al. Ten year results of the treatment of primary operable breast cancer. Cancer 38:1001–1007, 1976.
Haagensen CD. Treatment of curable carcinoma of the breast. Int J Rad Oncol Biol Phys 2:975–980, 1977.
Fisher B, Slack N, et al. Ten year followup results of patients with carcinoma of the breast in a cooperative clinical trial evaluating systemic adjuvant chemotherapy. SGO 140: 528–534, 1975.
Valagussa P, Bonadonna G, et al. Patterns of relapse and survival following radical mastectomy. Cancer 41:1170–1178, 1978.
Martin JK, van Heerden JA, Taylor WF, and Gaffey TA. Is modified radical mastectomy rally equivalent to radical mastectomy in treatment of carcinoma of the breast? Cancer 57, 1986.
Carter C, Allen C, and Hanson PE. Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases. Cancer 63:181–187, 1989.
Ribeiro G and Swindell R. The Christie hoispital adjuvant tamoxifen trial-status at 10 years. Br J Cancer 57:601–603, 1988.
Preliminary analysis by the CRC adjuvant breast trial working party (Abram WP, Baum M, Berstock DA, et al.). Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br J Cancer 57:604–607, 1988.
Baum M, Brinkley DM, and Dosset JA. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer: Analysis at eight years by ‘Nolvadex’ adjuvant trial organisation. Br J Cancer 57:608–611, 1988.
Fisher B, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breat cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479–484, 1989.
Bartlett K, Eremin O, Hutcheon A, et al. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Report from the Breast Cancer Trials Committee. Lancet, 171–175, 1987.
Fisher B, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 320:473–478, 1989.
Mansour EG, Gray R, Shatila AH, Osborne CK, Tormey DC, Gilchrist KW, Cooper MR, and Falkson G. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer: An intergroup study. N Engl J Med 320:485–490, 1989.
The Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node negative breast cancer. N Engl J Med 320:491–495, 1989.
Senn H, Barett-Mahler A, Jungi W, and OSAKO. Adjuvant chemoimmunothrapy with LMF+BCG in node-negative and node-positive breast cancer patients: 10 year results. Eur J Clin Oncol 25:513–525, 1989.
Bonadonna G, Valagussa P, Zambetti M, Buzzoni R, and Moliterni A. Milan adjuvant trials for stage I-II breast cancer. In: Adjuvant Therapy of Cancer V, Grune and Stratton, Orlando, FL, eds. 1987, pp. 211–221.
Nissen-Meyer R, Host H, Kjellgren K, Mansson B, and Norin T. Treatment of node-negative breast cancer patients with short course of chemotherapy immediately after surgery. NCI Monogr 1, 1986.
Morrison J, Howell A, Kelly K, Grieve R, Monypenny I, Walker R, and Waterhouse J. West Midlands Oncology Association trials of adjuvant chemotherapy in operable breast cancer: Results after a median follow-up of 7 years. II Patients without involved axillary lymph nodes. Br J Cancer 60:919–924, 1989.
Fisher B, Redmond C, et al. Systemic therapy in patients with node-negative breast cancer. Ann Intern Med 111:703–712, 1989.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ahmann, D.L. (1992). The node-negative problem. In: Henderson, I.C. (eds) Adjuvant Therapy of Breast Cancer. Cancer Treatment and Research, vol 60. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3496-9_6
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3496-9_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6550-1
Online ISBN: 978-1-4615-3496-9
eBook Packages: Springer Book Archive